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Abstract Combination therapy with pegylated interferon
and ribavirin is the standard of care (SOC) for the treatment
of chronic hepatitis C (CHC). Treating CHC with SOC
may show a sustained virological response (SVR) in
approximately 50–70 % of genotype 1 CHC patients and
an SVR in 70–90 % of genotype 2 CHC patients. The
genotype, baseline viral load, and viral kinetics (i.e., rapid
virologic response and early virologic response) can be
used as predictors of response-guided therapy. Nonethe-
less, host factors, e.g. age, ethnicity, insulin resistance, and
genetic variations, may also play important roles in the
SVR in CHC patients treated with SOC. Recent genome-
wide association studies have demonstrated that single-
nucleotide polymorphisms near the interleukin 28B gene
(IL28B) were associated with SVR to treatment with SOC
in CHC patients. The IL28B polymorphisms may contrib-
ute to the viral kinetics during treatment. Asian people
have favorable IL28B polymorphisms. This factor may at
least partly explain the high eradication rate of hepatitis C
by SOC in Asia. Combination therapy with direct-acting
antivirals (DAAs) and SOC can increase the SVR rates
both in treatment-naı¨ve and treatment-experienced patients.
Although the IL28B polymorphisms also affect the SVR of
triple therapy with SOC and first-generation protease
inhibitors, pilot studies have demonstrated that potent
DAAs might overcome the influence of IL28B polymor-
phisms. Thus, the treatment of hepatitis C virus infection
could be simplified in the near future.
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Introduction
Hepatitis C virus (HCV) infection is one of the most
important health issues throughout the world. The esti-
mated worldwide prevalence of HCV infection is around
1–3 %. However, such crude estimates might mask sig-
nificant differences in prevalence rates among countries,
and even in different parts of the same country. According
to data reported by the World Health Organization,
worldwide, approximately 130–170 million people are
infected with hepatitis C, 3–4 million persons are newly
infected each year, and more than 350,000 people die from
hepatitis C-related liver diseases each year. Of patients
acutely infected with HCV, 50–80 % of them will even-
tually have chronic hepatitis. Once the chronic status is
established, the disease progresses gradually. In approxi-
mately 10–20 % of patients with chronic hepatitis C
(CHC), the disease will lead to liver cirrhosis in 20 years.
After the development of liver cirrhosis, the annual rates of
hepatocellular carcinoma occurrence are about 1–8 %.
Excessive alcohol intake and concurrent HIV infection will
accelerate the disease progression [1–8]. Therefore, the
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goals of treatment for hepatitis C are to decrease its
infectivity, to decrease the risk of cirrhosis or decompen-
sation, to decrease the development of hepatocellular car-
cinoma, and to improve the survival and quality of life of
the patients [1–14].
Standard of care and response-guided therapy
Interferon (IFN)-a was the therapeutic agent first
approved for chronic HCV infection, in the 1980s. With
IFN monotherapy, a sustained virologic response (SVR)
could be achieved in 6–20 % of patients with CHC in
Western countries [15–18]. However, the SVR rates were
much higher in Asian studies [4, 11–14, 19–22]. Higher
doses of IFN and longer durations of treatment may result
in higher SVR rates. The HCV genotype, HCV viral load,
and pre-existent cirrhosis are important predictors
of SVR in CHC patients receiving IFN monotherapy
[4, 11–22].
A pilot study by Lai et al. [23] demonstrated that the
addition of ribavirin in the treatment of CHC could sig-
nificantly increase the SVR rates. With conventional IFN
and ribavirin treatment, large-scale studies in Western
countries demonstrated that the SVR rates of a 24-week
regimen and a 48-week regimen in genotype 1 CHC
patients were 30–35 % and around 40 %, respectively [17,
18]. Again, the results from clinical trials in Taiwan
revealed higher SVR rates for combination therapy with
conventional IFN and ribavirin for only 24 weeks [22–25].
The addition of polyethylene glycol molecules to IFNs
(pegylation, forming pegylated [peg] IFNs) changes some
IFN characteristics, such that pegIFNs, compared with
conventional IFNs, show prolonged half-life in plasma,
reduced clearance, and decreased immunogenicity. Hence,
pegylated IFNs have a longer half-life and better efficacy
than IFNs. Combination therapy with pegIFN and ribavirin
achieved higher SVR rates than combination therapy with
conventional IFN and ribavirin [26–28]. Therefore, com-
bination therapy with pegIFN and ribavirin has become the
standard of care (SOC) for CHC, especially in most Asian
countries. The SVR rates with 48-week pegIFN and riba-
virin combination therapy in genotype 1 CHC were around
50 % in Western countries [26–30]. The SVR rates with
24-week pegIFN and ribavirin combination therapy in
genotype 2 CHC were higher than 80 % in Western
countries [28, 29, 31–33]. Surprisingly, studies in Asia
showed SVR rates of 70–80 % in genotype 1 CHC patients
treated with pegIFN and ribavirin for 48 weeks, and SVR
rates of 90–95 % in genotype 2 CHC treated for 24 weeks
[4, 34–38].
About 40 % of genotype 1 CHC patients achieved a
rapid virologic response (RVR) by SOC. The SVR rate was
90 % in patients with RVR who received the combination
therapy for only 24 weeks [36–38]. In genotype 1 CHC
patients with an RVR and low viral load, the SVR rate of
the 24-week regimen was as good as that of the 48-week
regimen. The SVR rates were 96 and 100 %, respectively
[37]. Approximately 90 % of the genotype 2 CHC patients
reached an RVR. In patients with an RVR, the SVR rates in
a 16-week group and a 24-week group were 100 and 98 %,
respectively [35]. The lack of an early virologic response
(EVR) in genotype 1 CHC is a critical predictor of a non-
responder [27, 37], with a negative predictive value of
100 % [37]. Against this background, a roadmap for indi-
vidualized HCV therapy in Asian people is suggested, as
follows. For genotype 1 CHC, the optimal treatment
duration is 48 weeks, but a 24-week regimen may be suf-
ficient for patients with an RVR and low viral load. For
genotype 2 CHC, the treatment duration is 24 weeks.
However, a short-term treatment with pegIFN and ribavirin
is effective for patients with an RVR. For patients without
an EVR, stopping the treatment is suggested because of the
poor response by SOC [4]. These suggestions are similar to
the recommendations made by the Asian Pacific Associa-
tion for the Study of the Liver (APASL), the American
Association for the Study of Liver Diseases (AASLD), and
the European Association for the Study of the Liver
(EASL) [4, 5, 7, 8].
Host factors determining the efficacy of hepatitis C
treatment
Besides the baseline virological factors, on-treatment viral
kinetics, and antiviral agents, host factors such as age,
insulin resistance, ethnicity, and genetic variations, may
also play important roles in the achievement of an SVR in
CHC.
The efficacy and safety of treating elderly CHC patients
are still controversial issues. It has been suggested that
elderly patients chronically infected with HCV might suf-
fer from more adverse effects on IFN-based therapy and
have higher rates of drug modification or discontinuation.
Thus, the elderly could have lower SVR rates to IFN-based
therapy [39–42]. However, various results have been
shown [43, 44]. In a prospective study by Huang et al. [44],
it was found that the treatment response was substantially
lower in elderly patients than in patients between the ages
of 50 and 64 years, especially in patients infected with
genotype 1 HCV. Also, the elderly patients, who received
48 weeks of treatment, had significantly higher rates
of grade 3 or 4 adverse side effects, dose modification,
and discontinuation. However, the per-protocol analysis
revealed that the elderly patients had an SVR rate similar to
that of the younger patients. In addition, elderly patients
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with an RVR showed high SVR rates that were comparable
to rates in the younger patients [44]. Thus, an individual-
ized therapy is more suitable for elderly patients. Short-
ening the treatment duration and reducing the drug-related
adverse events might enhance the treatment adherence of
the elderly and lead to a better response to the treatment for
CHC [45].
Since the introduction of IFN-a for the treatment of
CHC, it was found that SVR rates were much higher in
Asian people [4, 11–14, 19–22] than those reported in
Western studies [15–18]. The addition of ribavirin in the
treatment of CHC significantly increased the SVR rates and
decreased the relapse rates [23]. Large-scale studies in
Western countries demonstrated that the SVR rates with
conventional IFN and ribavirin treatment in genotype 1
CHC patients were around 30–40 % [17, 18]. However, the
SVR results in those studies were far less than the SVR
rates in Asian trials [22–25]. The pegIFN and ribavirin
combination therapy (SOC) might achieve higher SVR
rates than the combination therapy with conventional IFN
and ribavirin [26–28]. The SVR rates of pegIFN and
ribavirin combination therapy in genotype 1 and genotype
2 CHC in Western countries were around 50 and 80 %,
respectively [26–33]. However, the Asian studies showed
SVR rates of 70–80 % in genotype 1 CHC patients and
90–95 % in genotype 2 CHC [4, 34–38]. Furthermore, the
SVR rates to SOC in African Americans with chronic HCV
infection were also lower than those in Hispanic and
Caucasian Americans [46, 47]. These results implied that
ethnicity is a very important factor influencing the treat-
ment outcome of SOC to CHC [4].
There is an association between chronic HCV infection
and metabolic diseases, e.g., insulin resistance and lipid
synthesis disturbances [48, 49]. Several studies have pos-
tulated a strong association between chronic HCV infection
and increased prevalences of insulin resistance [50–52] and
type 2 diabetes mellitus [53–55]. The presence of insulin
resistance and diabetes mellitus might impair the response
to pegIFN and ribavirin combination therapy, and lead to a
lower SVR rate [56–58]. Interestingly, sustained suppres-
sion or clearance of HCV appeared to attenuate insulin
resistance, restore beta-cell function, and reduce glucose
abnormalities [59–64]. These findings strongly suggested a
causal relationship between chronic HCV infection and
insulin resistance.
CHC patients might have higher prevalences of various
immunological phenomena, including positivity for auto-
antibodies [65]. Antinuclear antibody (ANA), a marker of
autoimmune liver disease and other inflammatory condi-
tions, is often detected in patients with chronic HCV
infection [66]. ANA seropositivity has been found to be
correlated with lower HCV RNA levels, old age, and
advanced fibrosis in CHC patients [67]. The response to
IFN or IFN and ribavirin combination therapy in ANA-
positive CHC patients was controversial [68–70]. No
differences between autoantibody-positive and autoanti-
body-negative patients in responses to IFN-based treatment
have been reported [68, 69]. But it has been found that
there is a tendency towards worse long-term responses in
autoantibody-positive patients [70]. A recent article dem-
onstrated that a high ANA titer ([1:80) was an independent
factor associated with SVR to pegIFN and ribavirin com-
bination therapy in HCV non-1 genotype patients [71].
However, the frequencies of adverse events with pegIFN
and ribavirin combination therapy were not increased in
these ANA-positive patients [71].
Tumor necrosis factor (TNF)-a is a pro-inflammatory
cytokine. It is an important pathogenic mediator in liver
diseases. TNF-a may be involved in the pathogenesis of
acute and chronic HCV infection, the persistence of the
virus, and the response to IFN therapy [72]. Some genetic
polymorphisms in the human TNF-a promoter region, such
as the G-to-A transition at positions -308 and -238, have
been shown to influence TNF-a expression. At position
-308, allele 2 (A; TNF308.2) is associated with higher
constitutive and inducible levels of TNF-a than is allele 1
(G; TNF308.1) [73]. At position -238, allele 2 (A; TNF
238.2) has been reported to be associated with certain
autoimmune and infectious diseases [74]. Although con-
flicting data on the associations between TNF-a promoter
polymorphisms and the pathogenesis and progression of
chronic HCV infection, and the response to IFN-a therapy,
have been reported [75], the TNF-a promoter polymor-
phism at position -308 may be helpful to predict the
response to combination therapy in genotype 1 CHC
patients, especially in genotype 1 CHC patients with a high
viral load [76].
Human leukocyte antigens (HLAs), encoded by the
major histocompatibility complexes, play an important role
in the host responses to infection [77, 78]. HLA class I and
class II molecules are pivotal to the host immune response
via presenting antigen to CD8? cytotoxic T cells and
CD4? helper T cells. Specific HLA alleles have been
reported to be related to the persistence or spontaneous
clearance of HCV, HCV viral load, progression of liver
fibrosis, and the antiviral response to conventional IFN
monotherapy [79–83]. HLA class I antigen was also shown
to be associated with an SVR to IFN and ribavirin com-
bination therapy in patients with CHC [84]. However, only
a few reports have studied the association between HLA
alleles and response to pegIFN and ribavirin combination
therapy [85]. A study conducted in Taiwan, aiming to
elucidate the association between HLA loci and responses
to pegIFN and ribavirin therapy, postulated that the HLA
A24 and B40 alleles were significantly associated with
SVR after adjustment for confounding factors including
24 J Gastroenterol (2013) 48:22–30
123
HCV genotype, hepatic fibrosis, and pretreatment serum
HCV RNA levels [85]. Regarding the HLA haplotypes,
B40-DRB1*3, B46-DRB1*9, Cw1-DQB1*3, and Cw1-
DRB1*9 were significantly associated with an SVR to
combination therapy [85]. These results suggested that host
immunogenetic factors may be used to predict the response
to combination therapy in CHC patients.
Genome-wide association studies (GWAS) of samples
from the IDEAL trial and another prospective treatment
study demonstrated that a host single-nucleotide polymor-
phism (SNP) near the interleukin 28B (IL28B) gene
(interferon lambda 3 gene) was strongly associated with
SVR to treatment with pegIFN and ribavirin in CHC
patients in all ethnic groups [86]. A Duke University group
also found that SNP rs12979860 C-allele frequencies were
different in diverse ethnic groups. The study by Ge et al.
[86] showed that the distribution of the IL28B polymor-
phism may, at least partly, explain the different SVR rates
to the same treatment regimen for CHC in different eth-
nicities [86]. A GWAS study of SVR to pegIFN and
ribavirin combination therapy in Australian patients with
genotype 1 CHC [87] presented a result similar to that of
the study by Ge et al. [86]. An association between IL28B
polymorphism and response to pegIFN and ribavirin
combination therapy was also reported by Tanaka et al.
[88] in Japanese patients with genotype 1 CHC. The IL28B
polymorphism was also significantly correlated with
spontaneous HCV clearance in patients with acute HCV
infection. Patients with the rs8099917 TT genotype had a
higher rate of spontaneous HCV clearance [89].
Liu et al. [90] postulated that RVR, IL28B polymor-
phism, treatment duration, and low viral load were inde-
pendent factors for SVR in Taiwanese patients with
genotype 1 chronic HCV infection treated with pegIFN and
ribavirin. Many studies showed that the IL28B polymor-
phism was strongly associated with RVR and SVR to the
treatment with SOC in genotype 1 CHC [86–88, 90–93].
However, further analysis demonstrated that the differ-
ences in SVR rates were not significant among RVR
patients with different IL 28B genotypes. Only in patients
without an RVR, the IL 28B polymorphism may influence
the SVR to pegIFN and ribavirin combination therapy
[91–93]. For genotype 1 CHC patients without an RVR, the
complete early virologic response (cEVR) is an important
predictor of SVR in patients treated with pegIFN and
ribavirin for 48 weeks [94]. It was found that the IL28B
polymorphism was an independent factor for SVR in
genotype 1 CHC patients without an RVR [91–93]. How-
ever, when cEVR was included in a multivariate analysis,
the role of the IL28B polymorphism was not significant
[93]. Therefore, the on-treatment viral kinetics is more
important than the IL28B polymorphism in determining the
response to pegIFN and ribavirin combination therapy in
CHC patients. The role of the IL28B polymorphism was
not so important in the treatment with SOC in genotype 2
and 3 CHC patients. The differences in SVR rates were not
statistically significant among different IL28B genotypes in
genotype 2 and 3 CHC patients [95–97]. An association of
the SNP rs72258881 polymorphism [a (TA) di-nucleotide
repeat located in the promoter region of IL28B] and IL28B
gene expression was postulated by Sugiyama et al. [98].
This genetic variation of the IL28B promoter may affect
the gene expression in a (TA)n length-dependent manner.
However, the significance of this polymorphism needs
further clinical validation.
Combined host and viral factors for personalized
genotype 1 HCV therapy
According to the suggestions in various guidelines [5, 7, 8],
a 24-week regimen may be sufficient for genotype 1 CHC
patients with an RVR and low viral load5, 7, 8. The SVR
rates were higher than 90 % in genotype 1 CHC patients
with an RVR and low viral load when treated with pegIFN
and ribavirin for 24 weeks [37, 38, 99–101]. However,
only 20–40 % of genotype 1 CHC patients met these cri-
teria. Is it possible to identify HCV genotype 1 super-
responders before starting antiviral therapy? The answer is
yes. IL28B genotype combined with baseline viral load
may help in identifying HCV genotype 1 patients who will
or will not benefit from a 24-week regimen before starting
the therapy. The positive predictive value of these two
factors was 80 % and the negative predictive value was
91 % [92].
According to the suggestions in the guidelines [5, 7, 8],
for genotype 1 CHC patients only with a partial early
virologic response (pEVR), the suggested duration for
pegIFN and ribavirin therapy was 72 weeks5, 7, 8. Can we
more precisely identify HCV genotype 1 patients who will
benefit from the 72-week regimen? For genotype 1 CHC
patients only with a pEVR, the 72-week-regimen group had
a lower relapse rate than the 48-week-regimen group in
patients carrying the IL28B rs12979860 non-CC genotype
[102]. So HCV-1 slow responders carrying the IL28B
rs12979860 non-CC genotype may benefit from extended
therapy to 72 weeks.
According to the suggestions in the guidelines [5, 7, 8],
the treatment in genotype 1 CHC patients should be stop-
ped if the patients have no EVR (less than 2 log10 IU/mL
viral reduction at treatment week 12) or if the serum HCV
RNA is still positive at week 24 of the treatment5, 7, 8.
Could this result be applicable to identify HCV genotype 1
patients who will not respond to 48 weeks of SOC before
week 12 of treatment? A combination of week 4 IFN-
responsiveness and IL28B genotype was used for
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predicting treatment failure [103]; the negative predictive
value for HCV RNA [10,000 IU/mL at week 4 of treat-
ment and non-TT genotype was 94 %. And the negative
predictive value for an HCV RNA reduction of less than
1 log10 IU/mL at week 4 of treatment was 92 %. With a
strategy of sequential stopping rules, 53.7 % (73/136) of
non-responders were identified (43.4 % at week 4, and
10.3 % more at week 12). As compared with a non-
responder detection rate of 40.4 % (using the classical
12-week stopping rule), the new sequential stopping rules
could detect more non-responders and could enable the
earlier stopping of the treatment [103].
The role of host factors in the DAA era
There are many direct-acting antiviral agents (DAAs)
under investigation, including protease inhibitors, RNA
polymerase inhibitors, and non-structure protein (NS) 5A
inhibitors [104, 105]. To date, only 2 first-generation pro-
tease inhibitors have been approved in the United States
and Europe. They are telaprevir and boceprevir [106–109].
Overall, triple therapy with the first-generation protease
inhibitors and SOC can increase SVR rates from 40 to
70 % in treatment-naı¨ve patients, and from 20 to 65 % in
treatment-experienced patients with genotype 1 CHC
[106–109]. Telaprevir has been approved in Japan. The
SVR rates in genotype 1 Japanese CHC patients treated
with telaprevir-based therapy for 24 weeks were around
70 %, even in treatment-experienced patients [110–112].
Nonetheless, the IL28B polymorphisms also affect the
SVR of triple therapy with SOC and first-generation pro-
tease inhibitors. In treatment-naı¨ve genotype 1 CHC
patients receiving triple therapy, the patients with the
IL28B CC genotype had higher SVR rates [106, 107]. The
same trend was also observed in treatment-experienced
genotype 1 CHC patients [108, 109].
Although the triple therapy with first-generation DAAs
and current SOC may increase SVR rates, the triple therapy
can enhance adverse events, such as anemia, skin rash, and
gastro-intestinal symptoms [106–109]. In addition, the
complexity of the treatment might influence adherence to
treatment, as has been shown in HIV-infected patients
receiving highly active antiretroviral therapy. CHC patients
receiving the triple therapy could be taking as many as 18
tablets per day for this antiviral therapy. Therefore, the
triple therapy may be limited to genotype 1 and genotype 4
treatment-naı¨ve CHC patients with a poor IL28B genotype
or without an RVR, and to genotype 1 and genotype 4
previous non-responders, especially in regions such as Asia
where people have a favorable IL28B genotype. For
patients with genotype 2 and genotype 3 HCV, and geno-
type 1 and genotype 4 patients with a good IL28B genotype
and/or RVR, the dual therapy with pegIFN and ribavirin
may be sufficient, unless ultra-short triple therapy is proven
to be effective.
A pilot study conducted by Chayama et al. demonstrated
that potent DAAs might overcome the influence of IL28B
polymorphisms in Japanese CHC patients [113]. An NS5A
inhibitor (daclatasvir) and an NS3 protease inhibitor
(asunaprevir) were used for genotype 1 CHC null
responders. The results were quite exciting. Nine out of the
10 genotype 1b patients had achieved an SVR at week 24
after the end of treatment. The patient who discontinued
the treatment at week 2 also showed negativity for serum
HCV RNA at week 24 of follow up. Lok et al. [114]
reported that the combination of an NS5A inhibitor and an
NS3 protease inhibitor with SOC was effective for Amer-
ican genotype 1 CHC null responders. The SVR rate was
90 %. Although the SVR rate for the IFN and ribavirin-free
regimen was only 36 %, both of the patients with genotype
1b HCV obtained an SVR [114]. Gane et al. further dem-
onstrated that combination therapy with an NS5B RNA
polymerase inhibitor and ribavirin for 12 weeks achieved
an SVR of 100 % in treatment-naı¨ve genotype 2 and 3
CHC patients [115]. The major genotypes of HCV in East
Asia are genotypes 1b, 2, and 3. Therefore, we believe that
the eradication of HCV with an IFN and ribavirin-free
regimen will come true in the near future in East Asia.
Summary
In summary, combination therapy of pegIFN and ribavi-
rin is still the SOC for the treatment of CHC in most
Asian countries. As well as baseline virological factors,
on-treatment viral kinetics, and antiviral agents, host fac-
tors may also play important roles in SVR. The IL28B
polymorphism is strongly associated with the response to
SOC in genotype 1 CHC. The IL28B genotype combined
with baseline viral load and on-treatment viral response
may help in identifying genotype 1 CHC patients who will
or will not benefit from a 24-week regimen, as well as
helping to identify the HCV genotype 1 slow responders
who will benefit from extended therapy to 72 weeks, and
predicting the genotype 1 CHC patients who will encounter
a treatment failure with the SOC. Combination therapy
with DAA and SOC can increase the SVR rates in
both treatment-naı¨ve patients and treatment-experienced
patients. In treatment-naı¨ve and treatment-experienced
genotype 1 CHC patients receiving triple therapy the
patients with an IL28B favorable genotype still had higher
SVR rates. Pilot studies have demonstrated that potent
DAAs might overcome the influence of IL28B polymor-
phisms. Nonetheless, the role of DAA treatment in Asian
CHC patients needs further investigation.
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